曲罗芦单抗治疗中重度特应性皮炎的研究进展
Research progress of tralokinumab for the treatment of moderate and severe atopic dermatitis
张金桂 1王超2
作者信息
- 1. 海南省人民医院Ⅰ期临床试验病房,海口 570311
- 2. 琼海市人民医院药学部,琼海 571400
- 折叠
摘要
曲罗芦单抗(tralokinumab)是由丹麦利奥制药有限公司(LEO pharma)研发的一种白细胞介素13选择性抑制剂,于2021年12月27日被美国食品药品监督管理局批准用于治疗18岁或以上、疾病无法通过局部处方疗法充分控制或治疗的中重度特应性皮炎成人患者.本文对曲罗芦单抗治疗中重度特应性皮炎的研究进展作一综述.
Abstract
Tralokinumab is a selective interleukin-13 inhibitor developed by LEO Pharma in Denmark.It was granted approval by the US Food and Drug Administration on December 27,2021,for the treatment of patients aged 18 years or older with moderate to severe atopic dermatitis whose disease is refractory to or cannot be fully controlled by local prescription therapy.This article presents a comprehensive review of the recent research progress in the treatment of moderate to severe atopic dermatitis with tralokinumab.
关键词
皮炎,特应性/化学,药物/临床研究/药代动力学/吸收,理化/生物转化/药物相关性副作用和不良反应/药物评价,临床前/曲罗芦单抗Key words
Dermatitis,atopic/Chemistry,pharmaceutical/Clinical study/Pharmacokinetics/Absorption,physicochemical/Biotransformation/Drug-related side effects and adverse reactions/Drug evaluation,preclinical/Tralokinumab引用本文复制引用
出版年
2024
NETL
NSTL
万方数据